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There has been substantial improvement in survival of
children with cancer in high-income countries. How-
ever, great challenges remain in low- and middle-
income countries, where . 80% of children with
cancer live.1 Survival in many countries in Africa, for
example, is estimated to be , 20%.2 The WHO re-
cently launched the Global Initiative for Childhood
Cancer (GICC), which aims to increase survival of
children with cancers worldwide to. 60% by 2030 by
promoting access to high-quality cancer care for all
children and with an initial focus on common and
curable cancer types.3
As a group of pediatricians caring for children with
cancer in Africa, we recognized the need to focus on 3
activities—quality service provision, local data, and
locally relevant clinical research—to allow us to im-
prove outcomes together. We realized that service
provision would not improve if we continued to rely on
fragmented protocol development and outcome as-
sessment at separate units. We required local data to
develop locally relevant, collaborative studies to find
sustainable solutions to local challenges that will result
in substantial and sustained long-term gains. On the
basis of these 3 pillars of quality service, local data, and
locally relevant research, we are committed to co-
ordinate research to establish and promote best
practices within our network.
Oncology units in well-resourced settings have benefit-
ted greatly from multicenter collaborations in all aspect
of cancer care delivery, resulting in improved outcomes
for children with cancer. Multicenter collaborations can
and should be global in their design and value.4 Ac-
curate local data on numbers of patients on treatment,
accuracy of diagnosis, causes of treatment failure, and
the efficacy of specific interventions are required to in-
form the strategies for improved care and outcomes.
Our aim is to increase the survival of children with
common and curable cancers in Africa to exceed
60%, in line with the WHO GICC.
With the same goal in mind, the Collaborative Wilms
Tumor Africa project was formed in 2014 and has
been implementing a consensus-adapted treatment
guideline in 8 centers in sub-Saharan Africa as
a multicenter clinical trial.5 This guideline was
developed by the Committee for Pediatric Oncology
in Developing Countries (PODC) of the International
Society of Paediatric Oncology (SIOP).6,7 Currently
participating centers are in Blantyre (Malawi); Eldoret
(Kenya); Accra and Kumasi (Ghana); Mbingo, Banso,
and Mutengene (Cameroon); and Harare (Zimbabwe).
Funding was received from SIOP and World Child
Cancer and distributed to all participating centers to
cover treatment, travel, and other associated costs for
patients.
In the first 4 years of the trial (2014-2018), 201 pa-
tients were included. After implementation, compared
with the baseline evaluation, survival without evidence
of disease at the end of treatment increased (69% v
52%, respectively; P = .002), abandonment of treat-
ment declined (12% v 23%, respectively; P = .009),
and fewer patients died during treatment (13% v 21%,
respectively; P = .06).8 Two-year event-free survival
was 49.9% 6 3.8% in this patient cohort when
abandonment of treatment was considered an event.9
The Collaborative Wilms Tumor Africa Project Phase II
is planned to start in the second half of 2020 and
aims to improve survival further. There are minor revi-
sions to the comprehensive adapted treatment guide-
line based on lessons learned in Phase I.10
After establishing, implementing, and evaluating
initial treatment guidelines, we analyzed clinical data
and recognized that the major barrier to using more
intensive treatment regimens was the lack of opti-
mal supportive care.9 In 2019, Supportive Care for
Children With Cancer in Africa (SUCCOUR) was
initiated, with a goal to improve supportive care and
reduce treatment-related mortality further. Building
on the regional network of the Collaborative Wilms
Tumor Africa Project and the lessons learned,
SUCCOUR aims to promote improvements in sup-
portive care for every child in Africa to be able to be
cured from cancer.
We are currently conducting a baseline evaluation of
current practices and outcomes in the following im-
portant areas of supportive care: malnutrition, febrile
neutropenia, abandonment, and treatment-related
mortality. This baseline evaluation will be fundamen-
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facilitate the development and prioritization of supportive
care interventions. It will provide a benchmark for future
evaluation of the impact of implemented interventions.
Abandonment, or incomplete treatment, is known to be an
important problem in our centers, and our goal will be to
reduce it to zero. Hence, the third project, Toward Zero
Percent Abandonment, was started in Blantyre, Malawi, in
2019. It aims to eliminate incomplete treatment. Aban-
donment of treatment is a known common and preventable
cause of treatment failure in low-income countries.11 The
baseline evaluation of this project in Malawi documen-
ted that 49 (19%) of 264 patients diagnosed in 2018 and
2019 with common and curable cancers had abandoned
treatment.12 Interventions in Malawi to prevent abandon-
ment include full coverage of treatment, accommodation
and transport costs, a tracking system to remind patients of
appointments, and more systematic and improved coun-
seling of parents of the need to complete treatment. We
intend to introduce this project in all participating centers
over the next 1-3 years.
The Collaborative Wilms Tumor Africa Project, SUCCOUR,
and Toward Zero Percent Abandonment form the current
core of the Collaborative African Network of Clinical Care
and Research for Childhood Cancer (CANCaRe Africa). We
see the network as a platform on which to build these
collaborative studies with the intention that other studies
can and will be added to create change. The vision of
CANCaRe Africa is that children with common and curable
cancers in sub-Saharan Africa will achieve survival rates
. 60%-70%, in line with the GICC. The mission is to achieve
this by reducing treatment-related deaths to , 10%; re-
ducing abandonment of treatment to , 10%; and de-
veloping, implementing, and evaluating locally appropriate
treatment guidelines.
CANCaRe Africa has collaborated and aligned with other
national and international initiatives. We are sharing our
best practices with the WHO GICC, allowing our platform,
experience, and knowledge to serve the broader com-
munity. Collaborative research and innovation are essential
to achieving the targets established by the WHO initiative,
and we are actively supporting these WHO workstreams.
Collaborative research and innovation are essential to
achieving the targets established by the WHO GICC; we are
actively supporting WHO workstreams related to estab-
lishing treatment standards, to incorporating supportive
care programs as part of universal health coverage, and
to defining core indicators used in monitoring programs
and research. SIOP, including SIOP Africa and SIOP
PODC, is the global scientific pediatric oncology umbrella
organization.13 We collaborate within the SIOP community
to learn from other groups, develop our guidelines, and
implement and evaluate them according to robust scientific
standards. We also work closely with our national gov-
ernments, allowing for sustainable uptake of our programs
in the public sector. Current funding for the activities of this
regional network comes from SIOP, World Child Cancer,
and the Sanofi Espoir Foundation, who share our vision. We
hope to expand these partnerships and include others to
have sustainable and hopefully increased funding to deliver
on our aims and objectives.
Over the past few years, we have learned many lessons.14
We do work according to a shared vision, mission, and
principles by designing feasible interventions, achieving
incremental steps, and ensuring long-term sustained im-
pact. We give priority to interventions with the highest
expected impact on child survival, cognizant of the current
profound inequalities. Our philosophy is that local leaders
are in the best position to assess feasibility of interventions
and set priorities. Transparency, trust, and a shared pur-
pose are essential. We work through national institutional
review boards, ensure the validity of our results, and rou-
tinely report successes and challenges internally and ex-
ternally. Friendship, good communication, and comradery
are facilitators in achieving our vision and at the core of our
success.
We have established an active regional network for child-
hood cancer that can be a platform for further initiatives to
improve care and survival, including but not limited to the
WHO GICC. This is only the beginning of our work. To-
gether, we are finding sustainable solutions to shared local
challenges for children with cancer in our community and
around the world.
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